Based on the Novozymes AS stock forecast from 0 analysts, the average analyst target price for Novozymes AS is not available over the next 12 months. Novozymes AS’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Novozymes AS is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Novozymes AS’s stock price was USD 62.59. Novozymes AS’s stock price has changed by -3.01% over the past week, -10.74% over the past month and -74.13% over the last year.
No recent analyst target price found for Novozymes AS
No recent average analyst rating found for Novozymes AS
Frequently Asked Questions About Novozymes AS (NVZMY) Stock
Stock Target Advisor's fundamental analysis for Novozymes AS's stock is Very Bearish.
Unfortunately we do not have enough data on NVZMY's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NVZMY's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on NVZMY's stock to indicate if its overvalued.
The last closing price of NVZMY's stock was USD 62.59.
Unfortunately we do not currently have any market capitalization data for NVZMY's stock.
Unfortunately we do not have enough analyst data on NVZMY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Novozymes AS's stock.
Sorry, we do not have any data on the number of employees for Novozymes AS.
Sorry we do not have any infomation available on Novozymes AS's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Frequently Asked Questions About Novozymes AS (NVZMY) Stock
Stock Target Advisor's fundamental analysis for Novozymes AS's stock is Very Bearish.
Unfortunately we do not have enough data on NVZMY's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NVZMY's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on NVZMY's stock to indicate if its overvalued.
The last closing price of NVZMY's stock was USD 62.59.
Unfortunately we do not currently have any market capitalization data for NVZMY's stock.
Unfortunately we do not have enough analyst data on NVZMY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Novozymes AS's stock.
Sorry, we do not have any data on the number of employees for Novozymes AS.
Sorry we do not have any infomation available on Novozymes AS's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NVZMY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
